Valuation: AstraZeneca PLC

Market Cap 26TCr 22TCr 21TCr 19TCr 36TCr 24,68000Cr 37TCr 2,47500Cr 97TCr 12,08500Cr 97TCr 94TCr 41,61100Cr P/E 2026 *
20.7x
P/E 2027 * 18.2x
Enterprise Value 28TCr 24TCr 22TCr 21TCr 39TCr 26,52300Cr 40TCr 2,66000Cr 1,04400Cr 12,98800Cr 1,03700Cr 1,01400Cr 44,72000Cr EV / Sales 2026 *
4.37x
EV / Sales 2027 * 4.03x
Free-Float
96.63%
Yield 2026 *
2.02%
Yield 2027 * 2.13%

Last Transcript: AstraZeneca PLC

Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-8.57%-.--% - - 26TCr
-1.24%-6.38%+47.49%+154.57% 1,02800Cr
-0.69%-4.02%+62.93%+58.93% 61TCr
+1.42%-2.79%+31.81%+82.22% 43TCr
+1.10%-1.40%+29.49%+23.12% 32TCr
-0.57%-3.38%+26.63%+43.24% 28TCr
+3.21%+2.00%-23.90%-38.51% 22TCr
+0.53%-2.98%+22.05%+56.69% 19TCr
+1.07%-3.87%+19.72%+68.51% 16TCr
+1.38%+2.20%-0.12%-31.46% 14TCr
Average -0.24%-3.61%+24.01%+46.37% 37.55TCr
Weighted average by Cap. -0.53%-4.62%+35.55%+76.68%

Financials

2026 *2027 *
Net sales 6.32TCr 5.52TCr 5.11TCr 4.72TCr 8.89TCr 6,07200Cr 9.05TCr 61TCr 24TCr 2,97300Cr 24TCr 23TCr 10,23800Cr 6.68TCr 5.84TCr 5.4TCr 4.99TCr 9.39TCr 6,41600Cr 9.56TCr 64TCr 25TCr 3,14200Cr 25TCr 25TCr 10,81800Cr
Net income 1.24TCr 1.09TCr 1TCr 927.89Cr 1.75TCr 1,19400Cr 1.78TCr 12TCr 4.7TCr 58TCr 4.67TCr 4.57TCr 2,01300Cr 1.39TCr 1.22TCr 1.13TCr 1.04TCr 1.96TCr 1,33900Cr 1.99TCr 13TCr 5.27TCr 66TCr 5.23TCr 5.12TCr 2,25700Cr
Net Debt 1.92TCr 1.68TCr 1.55TCr 1.43TCr 2.7TCr 1,84400Cr 2.75TCr 18TCr 7.26TCr 90TCr 7.21TCr 7.05TCr 3,10900Cr 1.19TCr 1.04TCr 964.99Cr 891.54Cr 1.68TCr 1,14700Cr 1.71TCr 12TCr 4.52TCr 56TCr 4.49TCr 4.39TCr 1,93500Cr
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
165.66USD
Average target price
212.83USD
Spread / Average Target
+28.48%

Quarterly revenue - Rate of surprise